Eosinophilic Granulomatosis With Polyangiitis (egpa) Clinical Trials
2 recruiting trials for Eosinophilic Granulomatosis With Polyangiitis (egpa). Eligibility criteria explained in plain English.
TrialFinderData lists 2 Eosinophilic Granulomatosis With Polyangiitis (egpa) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 3 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by AstraZeneca (1), University of Pennsylvania (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Benralizumab (drug, 1 trial), followed by Online questionnaires.
Track Eosinophilic Granulomatosis With Polyangiitis (egpa) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
Vasculitis Pregnancy Registry
The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several online surveys to assess...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Eosinophilic Granulomatosis With Polyangiitis (egpa), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Eosinophilic Granulomatosis With Polyangiitis (egpa), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Eosinophilic Granulomatosis With Polyangiitis (egpa), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.